Together, these findings highlight the critical role of FGFR3 in bladder tumor carcinogenesis, raising the possibility of developing anti‐FGFR3 therapies for both NMIBC and MIBC (Chae et al, 2017). Here, FGFR3 is linked to urinary bladder neoplasm.